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INTRODUCTION
Uveitis involving the posterior segment encompasses a variety of 
infectious and noninfectious conditions, some of which are associated 
with systemic diseases. A thorough history, clinical examination, 
laboratory testing, and imaging are crucial in determining a diagnosis 
and subsequent treatment plan that can preserve vision. Evaluation and 
management of posterior uveitis varies globally because of geographic/
ethnic variation in its causes, differences in local practices, and varying 
access to diagnostic modalities and treatments. 
This case-based program captures the highlights of a roundtable 
discussion, in which an international panel of uveitis subspecialists 
provides expert perspectives on the diagnosis and management of 
uveitis involving the posterior segment, including the role of emerging 
diagnostic techniques and new and emerging therapies. The cases are 
from the files of Sunil K. Srivastava, MD.
Case 1: Differential Diagnosis – Infectious vs 
Noninfectious Uveitis
A 60-year-old man presents with a 4-day history of seeing a black 
spot in his central vision and light sparkles when staring at a dark 
background. He reports getting a shingles vaccine 4 weeks ago and 
being diagnosed with iritis 1 to 2 weeks thereafter. 
The patient is human immunodeficiency virus (HIV) positive and 
compliant with his antiretroviral therapy. He has hypothyroidism, 
hypertension, and hyperlipidemia. Results from laboratory tests taken 
2 months ago showed a CD4 count of 1032 cells/mm3 and undetectable 
viral load. Tests for gonorrhea, chlamydia, syphilis, and tuberculosis (TB) 
were negative. 
Visual acuity (VA) is 20/20 OD, 20/30- OS. The anterior chamber is 
deep and quiet OU. Figures 1 and 2 show color fundus and optical 
coherence tomography (OCT) images from the right and left eyes. 
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Figure 1. Fundus photographs reveal retinitis superior to the arcade in the 
right eye (A) and involving the fovea in the left eye (B)
Figure 2. Optical coherence tomography 
images of the left eye. Superior raster image 
displays outer retinal loss just superior to the 
fovea.
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4Dr Srivastava: Dr Taylor, what imaging do you perform when you see a 
new patient with posterior uveitis?
Dr Taylor: I get OCT and fluorescein angiography (FA). With FA, I might 
determine that there is more inflammation than I would have suspected 
according to the clinical appearance, and I can get a wide-field view.
Dr Srivastava: Dr Banker, what are your thoughts when you look at this 
patient’s FA images (Figure 3)?
Dr Banker: The lesion is quite well defined in both eyes, but more so in 
the left than in the right. There is a lot of staining, but not much leakage 
or nonperfusion, and there are only a few areas of mild peripheral 
perivasculitis temporally.
Dr Srivastava: This patient presented with a sudden onset of 
symptoms, and his condition is bilateral.  
Dr Taylor, do the history and imaging findings suggest any particular 
diagnosis for this patient?
Dr Taylor: Infectious retinitis is first on the list in the differential diagnosis of 
an HIV-positive patient, and midperipheral retinitis in someone who is HIV 
positive suggests syphilis, until proven otherwise. An inflammatory etiology 
or a malignancy is also a possibility. 
Dr Srivastava: When the patient was sent to me, the differential 
diagnosis included central serous retinopathy, but I think this is unlikely, 
given the retinitis. An infectious process is certainly in the differential 
diagnosis whenever there is retinitis, and I think about infection first 
whenever I see uveitis in a patient who is HIV positive. The most 
common etiologies of infectious uveitis in the United States are syphilis, 
toxoplasmosis, and viruses. Lymphoma and sarcoidosis would be other 
diseases to consider as well. 
Dr Banker: There is geographic variation in the causes of infectious 
uveitis in the HIV-positive population.1 In India, cytomegalovirus retinitis 
is still the most common infectious ocular manifestation that is seen in 
these patients, followed by toxoplasmosis.1,2 We also see other forms 
of viral retinitis, such as acute retinal necrosis and serpiginous-like 
choroiditis without vitritis. Ocular TB is being seen more commonly in 
this era of highly active antiretroviral therapy than it was before.1 
Dr Srivastava: Although infection is suspected, the patient recently had 
a laboratory workup that was negative for a variety of infections.
What would you do now?
Dr Sharma: A previous negative workup for infection does not rule out 
infection, and this is especially true in an HIV-positive patient. I would 
reorder the laboratory tests.
Case 1, Continued 
The laboratory workup was repeated, and the serology came back 
positive for syphilis (immunoglobulin G [IgG] > 8; rapid plasma reagin 
[RPR] 1:256).
Dr Sharma: At the Cleveland Clinic’s laboratory, the algorithm for 
syphilis serology testing recommends measuring IgG first, followed 
by RPR if the IgG test result is positive.3 The rationale for not doing 
RPR first is that it can give a false-positive result in a number of 
situations, including autoimmune disease, acute viral infection, recent 
immunizations, or drug addiction, and it can give a false-negative result 
in patients with latent or late syphilis.3
Dr Srivastava: At the Cleveland Clinic, this patient would be treated 
immediately with intravenous penicillin. Would anyone treat the patient 
differently?
Dr Sharma: Penicillin remains the treatment of choice for syphilis.4 If the 
patient reports an allergy to penicillin, doxycycline can be used initially, 
but the patient should have a skin test for penicillin allergy to determine 
if the allergy is real. If it is, desensitization for penicillin should be 
considered.
Dr Srivastava: Let us assume that syphilis was not diagnosed, and the 
patient was started on systemic corticosteroid therapy for the uveitis. 
How should the patient be followed? 
Dr Banker: You want to make sure that infection was not missed 
because infectious posterior uveitis can result in rapid vision loss.5 
Infectious uveitis will usually flare quickly after corticosteroid treatment 
is started, within 1 week. If the etiology of the uveitis is uncertain and 
infection has not been ruled out, the patient should be seen soon after 
starting a systemic corticosteroid. I would recommend a return visit in 
3 days.
 
Dr Sharma: It is important to point out that a corticosteroid should 
never be injected into or around the eye to treat uveitis unless infectious 
conditions have been ruled out with certainty. Local corticosteroid 
treatment can be considered after a patient is improving on an oral 
corticosteroid, but, as a caveat, some infectious uveitis can get better 
initially with corticosteroids, which help to resolve some of the acute 
inflammation seen with the infection. The patient, however, will rapidly 
worsen if the correct treatment is not started immediately.  
Dr Taylor: The worst cases of infectious uveitis that I have seen have 
been undiagnosed toxoplasmosis treated with intravitreal triamcinolone 
or the intravitreal dexamethasone implant. The problem with intravitreal 
treatment is that it cannot be easily withdrawn. Oral corticosteroids are 
less of a problem from this perspective, and in a situation in which there 
is dense vitritis, the corticosteroid may help to clear the vitreous enough 
so that it is easier to see evidence of infectious uveitis. If infection has 
not been ruled out, an oral corticosteroid can be given for a few days, 
without too much risk so long as the patient is monitored carefully.
Dr Srivastava: If you see a patient with posterior uveitis who is 
immunocompromised and you suspect infection, but are not certain 
about the exact etiology, how do you make the diagnosis?
 
Dr Banker: As a last resort, I would take the patient to the operating 
room to get a vitreous sample or retinal biopsy, but first, we consult the 
internist to get a complete systemic evaluation.
Dr Sharma: I am very cautious if I have a concern about an infection 
and try to get a sample from either the anterior chamber or the vitreous 
to send for polymerase chain reaction testing to detect viruses or 
toxoplasmosis. The yield from the anterior chamber sample is pretty 
good for viruses, including herpes zoster, varicella, and cytomegalovirus, 
but not as good for toxoplasmosis.6,7 If I am concerned about viral 
retinitis, I will start antiviral treatment orally or with an intravitreal 
injection while waiting for the test results before starting an oral 
corticosteroid.
Case 1, Continued
The patient was started on intravenous penicillin. After 14 days, there was 
resolution of the retinitis clinically, but still some hyperfluorescence on the 
FA (Figure 4A), raising consideration of persistent inflammation. Optical 
coherence tomography (Figure 4B) shows improvement in the outer retina, 
with the ellipsoid zone being visible again.
Figure 3. Late frame wide-field fluorescein angiography images reveal staining 
with mild leakage in both eyes
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Dr Srivastava: In my experience, inflammation can linger for a while 
in patients with syphilis. Do you see this, and if so, do you treat the 
inflammation with a topical or an oral corticosteroid?
Dr Taylor: Some patients will have a florid Jarisch-Herxheimer reaction 
when starting treatment for syphilis, which will require treatment with an 
oral corticosteroid, but I also see patients who have milder inflammation 
that I just observe for a while before deciding whether or not to treat.
Dr Sharma: Because of the potential for a Jarisch-Herxheimer reaction 
when patients with syphilis are started on intravenous penicillin, I will 
often add an oral corticosteroid to the intravenous penicillin, especially 
if there is an increase in inflammation on the clinical examination.
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Case 2: Multimodal Imaging for Diagnosis
A 50-year-old Indian male states that he had sudden onset of vision loss 
in his left eye. He went to the emergency room, was diagnosed with 
disc edema and elevated blood pressure, and was admitted for blood 
pressure control. He states he had mild improvement in his vision and was 
eventually seen by a neuro-ophthalmologist because of the disc edema. 
He was diagnosed with vasculitis. He presents 7 months after his initial 
onset of symptoms with persistent blurred vision with distortion.
Testing to date includes QuantiFERON-TB, angiotensin-converting 
enzyme, fluorescent treponemal antibody absorption, antineutrophil 
cytoplasmic antibody (ANCA), antinuclear antibody, chest x-ray, 
magnetic resonance imaging, and lumbar puncture. All results were 
negative.
Visual acuity is 20/40 OD, 20/60 OS, and there is trace cell in the 
anterior chamber OU. Fundus examination does not reveal any 
vitritis, and there are minimal changes on examination. Fluorescein 
angiography is obtained, and although the images are darker, there 
appears to be some hypofluorescence dark spots in the left eye 
along the superior arcade and nasal to the nerve (Figure 5A). The FA 
images of the right eye appear normal (Figure 5B). Optical coherence 
tomography imaging reveals normal retinal thickness, although the 
choroid may be a little thickened (Figures 5C and 5D).
 
Dr Srivastava: Dr Banker, what are your thoughts on the diagnosis and 
additional testing?
Dr Banker: In India, the diagnosis considered for a patient who presents 
with circumscribed lesions in the outer retina/choroid without overlying 
vitreous haze would be either TB or sarcoidosis. For a pulmonary 
evaluation, I would order a high-resolution chest computed tomography 
(CT), which is preferred over chest x-ray for diagnosing TB and 
sarcoidosis.1-3 We also have pulmonologists do bronchoalveolar lavage 
because analysis of the fluid has been shown to be useful for diagnosing 
sarcoidosis.4
Dr Sharma: Of note, a study from the Cleveland Clinic showed that 
chest CT was more sensitive than chest x-ray for identifying lesions of 
sarcoidosis in elderly women with uveitis.3 When there is suspicion for 
sarcoid, our pulmonologists prefer getting a high-resolution chest CT 
without contrast.
Dr Taylor: Ethnicity can be useful in creating the differential diagnosis 
for uveitis. For an Indian male with this presentation, TB and sarcoidosis 
would be at the top of the list. To better understand whether the dark 
patches on the FA represent an abnormality or not, I would order 
indocyanine green angiography (ICGA), which would enable a better 
examination of the choroidal circulation. Although ICGA can be difficult 
to interpret, it can reveal pathology that is not immediately apparent or 
that is unclear on FA.
Dr Sharma: Although this is not an enhanced depth imaging (EDI) 
OCT, we cannot see the outer borders of the choroid, and it appears 
to be thickened in both eyes, which suggests there is something 
happening deeper to the retina. I order ICGA as part of my initial 
workup in patients with uveitis only if I think it will be useful according 
to the findings of my examination, such as if I see deeper lesions or 
a thickened choroid on OCT, or if there are no changes on the FA 
that might explain the vision loss. I would get an ICGA in this patient, 
considering there is some evidence of choroid changes and there are no 
findings on FA to explain the moderate vision loss.
Dr Srivastava: Multimodal imaging can be valuable in the diagnostic 
evaluation of patients with uveitis. Because there were just some subtle 
findings on the OCT and FA, I ordered ICGA, which showed multiple 
hypocyanescent lesions (Figure 6). The diffuse hypocyanescent lesions 
provide a clue to the diagnosis. 
Would you get any other imaging?
A B
Figure 4. Left eye images from 14 days after starting treatment with 
intravenous penicillin. Fluorescein angiography displays late hyperfluorescence 
consistent with staining or leakage (A). Optical coherence tomography (B) 
reveals recovery of the outer retinal structures (ellipsoid zone and external 
limiting membrane) superior to the fovea.
Figure 5. Images from fluorescein angiography (A and B) and from optical 
coherence tomography (C and D)
A B
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6Dr Banker: I get EDI OCT almost routinely now. I think it is very 
helpful in cases with leakage on FA because findings on the EDI OCT 
allow me to differentiate Vogt-Koyanagi-Harada (VKH) disease from a 
sarcoid nodule or a tuberculous nodule. With VKH, there is thickening 
of the larger choroidal vessels, overlying subretinal fluid in acute 
leakage cases, and loss of the choriocapillaris layer. I do not have OCT 
angiography (OCTA), but I think some people are using it to study the 
capillary plexuses at various levels in the retina and are able to see very 
early changes in VKH.
Dr Srivastava: Dr Sharma, I know you use OCTA. Do you think it would 
be helpful in this case?
Dr Sharma: I have been doing OCTA because I think we need more 
experience with it to determine how it can help diagnose patients with 
uveitis.
 
Dr Taylor: I think OCTA may have the best utility in follow-up to 
minimize repeated use of invasive dye-based imaging. In general, I do 
not repeat the FA very often if a patient is doing well, but I will order it 
again if the disease is not under control because it gives me something 
I can follow over time. The same is true for EDI OCT.
Dr Sharma: What do you use as an objective measure for determining 
activity in a case like this, in which the only abnormal finding was on 
ICGA? If the patient’s vision improved to 20/20, would you conclude 
that he is doing well and not do any further imaging?  
Dr Srivastava: I think Dr Sharma’s question makes the important point 
that sometimes we have to pick an imaging test that we can follow as an 
end point for treatment. I would not expect in this case that all the spots 
seen on ICGA will go away, no matter what the cause is. Therefore, 
in deciding whether or not to repeat the imaging, we need to decide 
which finding will represent controlled disease. 
The differential diagnosis for this case would include TB, lymphoma, 
sarcoidosis, and birdshot retinochoroidopathy (BSRC). In the United 
States, BSRC might be at the top of the list if the patient was not an 
Indian male, and the resident who first saw this patient ordered a human 
leukocyte antigen A29 (HLA-A29) test that came back positive. 
Dr Taylor spoke about ethnicity giving us a clue. Has anyone seen BSRC 
in an Indian male?
Dr Banker: I have not diagnosed anyone, but I have heard of a few 
cases.
Dr Sharma: I also have not diagnosed BSRC in an Indian male. It is 
worthwhile noting that when used as a test for diagnosing BSRC, 
HLA-A29 has a positive predictive value of less than 50%, meaning it 
will be wrong more often than it is right.5 Therefore, in a patient like this 
who does not have lesions characteristic of BSRC on fundus imaging or 
FA, a positive HLA-A29 test is not informative.  
Dr Srivastava: What we need to think about when ordering testing is 
Bayes theorem and the probability that the test will be positive.6
In Cleveland, many cases of uveitis are BSRC, infectious, or sarcoid 
related. I tailor my workup with this in mind, so I order a lot of chest CTs. 
This patient had a chest CT and bronchoscopy, with detection of sarcoid 
lesions.
Dr Taylor, is there anything else you would do to determine the 
diagnosis in this case? 
Dr Taylor: When sarcoid is suspected, we generally start by measuring 
serum angiotensin-converting enzyme and getting a chest x-ray. If these 
tests are negative but suspicion for sarcoid is high, we refer to the chest 
physicians who would probably order a high-resolution chest CT, and it 
would be their decision whether to do a biopsy or lavage.
Following these principles, I think a retina specialist could investigate 
and manage this type of case and would not have to refer the patient to 
a uveitis specialist. Referral makes sense if the diagnosis is in doubt or if 
the disease is difficult to control.
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Case 3: Systemic Therapy
A 60-year-old woman presents at the emergency room with severe pain 
and sudden onset of vision loss in her left eye. Examination of the left eye 
shows VA of 20/100 and scleritis. The right eye is completely normal.
The fundus image of the left eye shows sheathing along the superior 
vessel and hemorrhage into the macula and in the nerve fiber layer, 
along with white-centered hemorrhage and whitish lesions extending 
out into the periphery (Figure 7).  
A late frame of the FA shows staining of the vessels and 
hyperfluorescence of the disc and a peripheral lesion (Figure 8). 
On OCT, there is hyperreflectivity in the middle layer (Figure 9).
 
Dr Srivastava: What are your thoughts on the diagnosis?
Dr Sharma: The retinitis is worrisome because it suggests infection, 
which would be important to rule out. The scleritis and other findings, 
however, raise concern that there may be something else going on.  
Dr Taylor: The combination of scleritis and what looks like optic disc 
vasculitis suggests that this is a very active inflammatory process. 
Antineutrophil cytoplasmic antibody–associated vasculitis would be 
at the top of my differential diagnosis. Some evidence suggests that
ANCA-associated vasculitis is becoming more common.1 Because 
Figure 6. Indocyanine green angiography reveals diffuse hypocyanescent 
spots throughout the macula in both eyes
Figure 7. Fundus 
photograph of the left eye 
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this patient would probably need to be treated with reasonably heavy 
immunosuppression to get the vasculitis under control, I would want to 
make sure that the uveitis is not infectious.
 
Dr Srivastava: Malignancy is also a possibility. What management advice 
would you have for a community retina specialist who sees this patient at 
5:00 pm on a Friday and is faced with not knowing whether the uveitis is 
infectious or inflammatory and associated with systemic vasculitis?
Dr Sharma: Both of these situations are associated with a high risk of 
rapid vision loss, but I would advise covering for infection first. I would 
recommend doing a tap, if possible, to get a specimen for diagnostic 
evaluation, injecting an antiviral medication into the eye, and starting 
oral antiviral treatment or getting the patient into the hospital for 
intravenous antiviral therapy, along with systemic corticosteroids. 
Dr Banker: I would say the patient should be referred to a 
rheumatologist. Because it will probably take 2 or 3 days to get a 
complete workup done, I would recommend starting antiviral treatment 
with a systemic corticosteroid to manage the severe pain, which I expect 
this patient has, and the potential threat to vision from disc involvement. 
Dr Taylor: In a worrisome situation like this, in which the diagnosis has 
not been made, you need to treat for whichever condition can make 
the patient go blind in a hurry. I think you cannot go wrong treating for 
both viral disease and vasculitis by injecting an antiviral agent such as 
foscarnet, which will cover more than 1 virus, and starting high-dose 
systemic corticosteroid treatment. It is also useful to do a vitreous tap 
to help with the diagnosis because otherwise, when the patient begins 
to improve, you will not know which treatment made a difference and 
which should be continued.
Dr Srivastava: Foscarnet is a great choice for antiviral treatment, but if 
it is not available, then high-dose systemic valacyclovir is a good option. 
The evaluation should also include a good review of systems.
Case 3, Continued
The patient was seen through the emergency room because she also 
complained of shortness of breath and coughing up blood. She is sent 
for a chest CT scan, which is abnormal, and she is admitted into the 
hospital. The patient is given an intravitreal antiviral injection as part 
of her initial treatment in the hospital. On the floor, her blood oxygen 
saturation falls and she is transferred to intensive care. 
Testing shows a very elevated ANCA level, and a diagnosis of 
granulomatosis with polyangiitis (formerly Wegener granulomatosis) is 
made based on evaluation of tissue from a lung biopsy. She was started 
on intravenous corticosteroids, and her scleritis improved significantly 
within a few days. 
Dr Srivastava: What would be your long-term management of the 
uveitis in this patient?
Dr Sharma: Granulomatosis with polyangiitis is a sight-threatening 
disease, and patients tend to do poorly unless they are kept on heavy 
immunosuppression. If intravenous corticosteroids are given just 
to quiet the inflammation and then stopped, there is a high risk of 
recurrence, which can occur with a rapid onset. 
I treat these patients aggressively and maintain them on either 
cyclophosphamide or rituximab. There is evidence showing that both 
these agents work well, and the choice between them is made in 
collaboration with the rheumatologist.2,3 
 
Dr Srivastava: In some cases of uveitis, we have to decide whether 
to treat locally or with systemic therapy, but here the decision is easy 
because the patient has a systemic disease with an ocular complication. 
Case 3, Continued
The patient was treated initially with intravenous cyclophosphamide and 
then transitioned to oral azathioprine. She was lost to follow-up and not 
seen for 6 months. On examination, her VA was 20/30 and there was some 
optic nerve cupping (Figure 10A) and areas of nonperfusion temporally, 
with late hyperfluorescence (Figures 10B-10D).
    
Subsequently, the patient stopped taking her azathioprine because of 
side effects. She was found unresponsive in her home, and it was thought 
that she had experienced a seizure related to cerebral vasculitis. She was 
started on intravenous rituximab. When next seen in the uveitis clinic 
6 years later, her vasculitis was inactive and her VA was 20/20 OD, 20/30 OS.
Dr Srivastava: This patient clearly needed to stay on systemic 
immunosuppressive therapy and maintain better follow-up. She is an 
example of a patient who needs a referral to a rheumatologist and/or 
a uveitis specialist. The complexity of her retinal disease and her 
systemic illness warrants a team-based approach for management. 
I often tell colleagues if they have a patient with severe retinal vasculitis 
with systemic signs, a prompt referral should be made to a uveitis 
specialist or a rheumatologist. In addition, physicians who are not 
familiar with immunosuppressive drugs (noncorticosteroids) should 
refer patients in whom these medications are warranted, per guideline 
recommendations (Table 1).4 
Figure 8. The late fluorescein angiography image from the left eye reveals 
leakage along the superior arcades and blockage from the hemorrhages
Figure 9. Optical coherence 
tomography imaging in the left 
eye reveals some inner and middle 
retinal hyperreflectance
Figure 10. Fundus (A) and fluorescein angiography images (B-D) of the left eye
A B
C D
8What is your first-line choice for a systemic corticosteroid-sparing 
agent for a patient who has uveitis that is not associated with systemic 
vasculitis?
Table 1. Indications for Immunosuppressive Therapy in Patients Diagnosed With Uveitis4
Dr Taylor: I prefer mycophenolate for adults and methotrexate for 
children. In my experience, azathioprine is less effective than these 
agents, and other corticosteroid-sparing immunosuppressive agents are 
often less well tolerated than mycophenolate and necessitate careful 
monitoring. Mycophenolate also needs careful monitoring, especially 
at treatment initiation, but the dosing is often simpler than that of other 
agents, which require more titration against treatment efficacy and side 
effects.4 I do not use cyclosporine at all anymore.
Dr Banker: I also prefer mycophenolate, but after mycophenolate, I use 
methotrexate and azathioprine about equally. The uveitis types we see 
in India, including juvenile idiopathic arthritis, sarcoidosis, intermediate 
uveitis, serpiginous choroiditis, and VKH, respond well to these 
agents.4,5
Dr Sharma: I also prefer mycophenolate for adults, but I find that 
neither mycophenolate nor methotrexate works that well for scleritis, 
and I would choose something different, such as rituximab, if there is 
very severe inflammation.
Dr Srivastava: How long does it take to see benefit after treatment with 
mycophenolate or methotrexate? 
Dr Sharma: Treatment with methotrexate is started at 10 to 15 mg/wk 
and titrated up by 5 mg every 2 weeks to 20 or 25 mg/wk.4 
A therapeutic response can be seen in 6 to 8 weeks.4 However, I tell 
patients it can take 3 months after reaching the full dose to begin to see 
a benefit. For mycophenolate, I find it takes approximately 2 months 
after reaching the full dose until we see an onset of effect.
Dr Srivastava: In June 2016, adalimumab, a monoclonal antibody 
targeting tumor necrosis factor-a, became the first noncorticosteroid 
agent approved by the US Food and Drug Administration for the 
treatment of noninfectious intermediate uveitis, posterior uveitis, and 
panuveitis in adult patients.6 Its safety and efficacy were demonstrated 
in patients with active and inactive disease in the VISUAL I (Figure 11) 
and VISUAL II pivotal trials, respectively.7,8 Both trials analyzed time to 
treatment failure as the primary end point.
Figure 11. Kaplan-Meier curves of the rate of treatment failure in patients 
receiving adalimumab vs placebo in the VISUAL I trial
Abbreviation: CI, confidence interval. 
From N Engl J Med, 375, Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in 
patients with active noninfectious uveitis, 375, 932-943, Copyright© 2016,  
Massachusetts Medical Society. Reprinted with permission from Massachusetts 
Medical Society.
Adalimumab is given as a subcutaneous injection, with recommended 
dosing of 80 mg initially, followed by 40 mg every other week.9 With 
copays, adalimumab can be less expensive than mycophenolate for 
patients in the United States. For this reason, adalimumab seems to 
be emerging as the first-line corticosteroid-sparing systemic agent for 
noninfectious posterior uveitis. I do not necessarily believe this shift is 
justified because we have much less experience with adalimumab than 
with other agents.
How is adalimumab being used at your centers?
Dr Sharma: I, too, am seeing a shift toward increased use of 
adalimumab now that it is covered by insurance, and patients like it 
because it involves a self-administered subcutaneous injection that is 
usually given just every 2 weeks,9 although I sometimes increase the 
frequency in very severe cases. 
Dr Taylor: In England, adalimumab can only be prescribed as third-
line treatment for patients who failed or are intolerant of other 
corticosteroid-sparing agents.10 
Dr Banker: In India, we have adalimumab and a biosimilar of 
adalimumab, but I agree that it is too early to be using adalimumab as 
a first-line corticosteroid-sparing agent, and rheumatologists seem to 
think so, too. 
One issue that limits the use of adalimumab in India is the high 
prevalence of TB. Patients are screened for TB before starting 
adalimumab and monitored for it while being treated. In addition, 
adalimumab is expensive for patients because there is no insurance 
reimbursement for it. 
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Management of disease not sufficiently controlled by systemic 
corticosteroids
• Add an immunosuppressive agent to initial high-dose oral  
 corticosteroid therapy if the disease…
 – Worsens
 – Fails to improve after 2 to 4 weeks
 – Is not completely quiet after 4 weeks
Inability to taper corticosteroid therapy to a safe dose
• Consider an immunosuppressive drug if chronic suppression  
 requires > 10 mg/d prednisone or its equivalent
As first-line therapy for certain types of uveitis, including Behçet 
disease with posterior segment involvement and mucous 
membrane pemphigoid with ocular involvement
Patients with certain underlying systemic diseases, including 
scleritis with systemic necrotizing vasculitis
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Case 4: Local Therapy
A 35-year-old woman with a history of bilateral intermediate uveitis reports 
declining vision in her right eye. She failed on methotrexate, refused 
cyclosporine, and has been on infliximab and methotrexate for many 
years. She started anti–tumor necrosis factor-a treatment with adalimumab 
before switching to infliximab 10 mg/kg monthly. She is also getting 
intravitreal triamcinolone injections occasionally for cystoid macular 
edema that seem to resolve the edema, but it generally recurs after 
approximately 2 months. 
Visual acuity is 20/80 OD, 20/20 OS. Fundus photographs reveal 
pigmentary changes peripherally and mild central haze from a cataract 
in the right eye, whereas the left eye appears normal. 
On OCT, there is intraretinal fluid, with irregularly shaped cysts in the 
foveal area (Figure 12). The ellipsoid zone and the external limiting 
membrane appear intact, but there are areas of retinal pigment 
epithelium loss.
 
Fluorescein angiography in the right eye shows staining and window 
defects temporally where the patient has pigmentary changes 
(Figure 13). She has significant retinal vascular leakage both in the 
periphery and in the macula. In the left eye (not shown), she has mild 
peripheral vascular leakage. 
  
Dr Srivastava: Judging from the irregularity, I believe the cysts have 
been present for a while. The pigmentary changes on the FA also tell 
me the inflammation has been smoldering for a long time, which makes 
me worry about visual potential in this patient. Because her ellipsoid 
zone and external limiting membrane appear intact, I think there is 
some potential for visual improvement. 
I think we all agree the disease in her right eye is active despite 
treatment with immunosuppressive medications. Therefore, she is at 
risk of developing peripheral nonperfusion with complications that can 
include schisis or detachment. What are your thoughts on treatment?
Dr Banker: I think she is a good candidate for a local therapy that 
has a sustained duration of action. The dexamethasone implant is 
the only option available in India, but there is no reimbursement for 
it. If a patient cannot afford the implant, he or she can continue with 
intravitreal triamcinolone, and I think even lower doses of 0.5 or 1 mg 
can be effective while posing a lower risk of intraocular pressure (IOP) 
elevation and cataract.
Dr Taylor: One could try cyclophosphamide for systemic 
immunosuppression, but that has quite significant implications for 
the patient, including an effect on fertility, which could be a particular 
concern for this 35-year-old woman, as well as the risk of late 
malignancy.1 I agree with Dr Banker that local therapy is really preferred 
for this patient, considering that she has active disease and vision loss in 
only 1 eye.  
Dr Srivastava: In the United States, we have access to the fluocinolone 
acetonide intravitreal implant, 0.59 mg. I used it in this patient and 
removed her early cataract at the same time because of the risk of 
cataract progression with the implant.2
Dr Sharma, what would be your end point for determining response to 
treatment in this patient? Would you look for inactivity on FA or OCT?
Dr Sharma: Fluorescein angiography helps me determine if the 
disease is active or not, and I order it quite often. Surrogate measures 
on OCT include changes in cystoid macular edema, thickening of the 
perivascular area, and nerve fiber layer thickness. With OCT, however, 
you cannot tell if there is active vasculitis in the periphery.
Case 4, Continued
Follow-up with FA shows an impressive response of the leakage within 
just a few months after placing a fluocinolone acetonide implant. At the 
1-year follow-up, the patient is off infliximab and methotrexate, and VA 
is 20/40. Figure 14 is an image from FA done at the 1-year visit. The 
patient developed elevated IOP that was managed with glaucoma tube 
surgery approximately 9 months after her fluocinolone implant surgery.
Dr Srivastava: Intravitreal sirolimus 440 µg is being developed as a 
local treatment for noninfectious uveitis involving the posterior segment. 
It is a mammalian target of rapamycin inhibitor that acts to block 
leukocyte activation and the production of inflammatory cytokines.
The primary and key secondary end points in the 2 phase 3 SAKURA 
(Sirolimus Study Assessing Double-Masked Uveitis Treatment) studies 
looked at vitreous haze, and results of an integrated analysis of data from 
both trials showed statistically significant differences favoring sirolimus 
440 μg over sirolimus 44 μg which was the control treatment (Table 2).3 
Other end points, which I consider to have greater clinical relevance, also 
suggested a benefit with sirolimus. Findings of the integrated analysis 
suggested sirolimus 440 μg allowed successful tapering of corticosteroid 
therapy (Table 2).4 
Figure 12. Optical coherence tomography horizontal scan reveals intraretinal 
edema (large arrows), with some focal retinal pigment epithelium loss (small 
arrows)
Figure 13. Fluorescein angiogram of the right eye. Early frame (A) reveals normal 
perfusion. Late frame (B) confirms staining and window defects temporally and 
retinal vascular leakage both in the periphery and in the macula.
Figure 14. Fluorescein 
angiogram of the right eye 
1 year after placing the 
fluocinolone acetonide 
intravitreal implant, 0.59 mg
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In addition, published data from SAKURA 1 showed that in the sirolimus 
440-μg group, patients with good vision at baseline maintained vision, 
whereas vision improved in patients with relatively poor vision at 
enrollment.5 Best-corrected VA data are not available from SAKURA 2. 
Importantly, sirolimus also had a favorable safety profile in SAKURA 1, 
with low rates of cataract and increased IOP.5 
Dr Taylor, what are your thoughts on the role of sirolimus as local 
therapy?
Dr Taylor: The downsides of local corticosteroid treatment are the 
risks of IOP elevation and cataract. Intraocular pressure can usually 
be controlled and cataract is not a big concern for older presbyopic 
patients. Nevertheless, any medication that avoids these side effects 
would be a big step forward, and the hope is that sirolimus will provide 
efficacy that at least approaches the benefit of corticosteroids, with less 
risk of cataract and IOP elevation.
Dr Srivastava: It appears that sirolimus may need to be given every 
2 months. Do you think patients with uveitis would accept this injection 
regimen?
 
Dr Sharma: Assuming that the visit can be reasonably short, I think 
patients would be happy to return every 2 months for a treatment that is 
effective and that has a favorable side-effect profile.
Dr Banker: Young patients are tired of being on systemic medications 
because of the side effects, which also affect their ability to work, so they 
are excited about the potential of local therapy with sirolimus. I have 
42 patients in my investigator-sponsored trial of sirolimus, with follow-
up to as long as 4 years (unpublished data). Patients are compliant with 
their return visits, and I have used sirolimus as primary therapy, with good 
results, in some patients. Quite a few patients have received 3 or 
4 injections and then did not need any treatment for 2 years.
Dr Srivastava: Emerging local therapies make this an exciting time in 
uveitis. We hope that sirolimus will be approved, and positive results 
have been reported with the injectable long-acting fluocinolone 
acetonide intravitreal implant after 2 years of follow-up in a small, 
investigator-sponsored study.6 In addition, results of a phase 1/2 study 
of suprachoroidal triamcinolone acetonide injection were encouraging 
because they supported the idea that the suprachoroidal route of 
administration might minimize the side-effect risks of local corticosteroid 
treatment.7
Having more options with new systemic and local therapies will enhance 
our ability to tailor therapy. A personalized approach will entail more 
work for the treating ophthalmologist, but with work under way by 
the Standardization of Uveitis Nomenclature working group to better 
classify disease phenotypes and by using our imaging technologies, 
I think we will have better ways to categorize patients, which will help 
guide treatment decisions. 
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TAKE-HOME POINTS
Accurate diagnosis of uveitis depends on a comprehensive assessment 
that should include a thorough history, ocular examination, review of 
systems, and laboratory evaluations chosen on the basis of sensitivity, 
specificity, and pretest probability.
Differentiating infectious uveitis from noninfectious uveitis is critical 
because infectious uveitis can be rapidly sight threatening.
Multimodal imaging may be needed to fully characterize pathology in 
patients with posterior uveitis.
Do not inject a corticosteroid into or around the eye for treatment of 
uveitis until an infectious cause has been ruled out.
Systemic treatment with immunosuppressive agents or biologics is 
indicated for posterior uveitis when inflammation cannot be controlled 
by a corticosteroid alone, if the corticosteroid cannot be tapered to a 
safe dose, and for management of certain underlying systemic diseases.
Do not hesitate to refer patients to a uveitis specialist if the diagnosis 
is uncertain, if the condition is not responding to the chosen therapy, 
if the uveitis is associated with a systemic disease, and if systemic 
immunosuppressive therapy is indicated and the ophthalmologist lacks 
familiarity with its use.
Subcutaneous adalimumab is the first and only noncorticosteroid 
medication that is approved by the US Food and Drug Administration 
for the treatment of noninfectious intermediate uveitis, posterior uveitis, 
and panuveitis.
Intravitreal sirolimus showed promising efficacy and safety in phase 3 
trials as a local therapy for noninfectious uveitis involving the posterior 
segment.
 
Intent-to-Treat Population*
Sirolimus 
44 µg
(n = 208)
Sirolimus 
440 µg
(n = 208)
P Value
Percentage with VH score = 0
(primary end point) 13.5 21.2 .038
Percentage with VH score = 0 or 0.5+ 
(secondary end point) 40.4 50 .049
Intent-to-Treat Population†
Sirolimus 
44 µg
(n = 32)
Sirolimus 
440 µg
(n = 46)
P Value
Percentage with corticosteroid-tapering 
success and VH score = 0 or 0.5+ 28.1 43.5 .168
Table 2. SAKURA Study Results: Data From Month 5 in an Integrated Analysis3,4
Abbreviations: SAKURA, Sirolimus Study Assessing Double-Masked Uveitis 
Treatment; VH, vitreous haze.
* All enrolled patients had VH score ≥ 1.5+ at baseline.
† Analysis included only patients on overall prednisone-equivalent dose > 5 mg/d 
at baseline; tapering success was defined as overall prednisone equivalent dose 
≤ 5 mg/d.
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1.  Prompt identification of an infectious cause for uveitis involving   
 the posterior segment is important because: 
 A.  All corticosteroids should be avoided until infection is 
  ruled out
 B. Hypotony can occur rapidly with untreated infectious uveitis
 C. The patient requires prompt referral to an ophthalmologist   
  with expertise in managing uveitis 
 D. Vision loss can occur rapidly with untreated infectious uveitis
2. Which of the following might be considered in an    
 immunocompromised patient with posterior uveitis when a viral   
 cause is suspected?
 A. Anterior chamber or vitreous tap to check for viruses
 B. Intracameral injection of an antiviral agent 
 C. Simultaneous corticosteroid and antiviral intravitreal treatment   
  while awaiting diagnostic confirmation
 D. Observation for progression
3.  Multimodal imaging may be needed for a comprehensive   
 diagnostic assessment of pathology in eyes with posterior uveitis,   
 and it might include all the following, EXCEPT:
 A. EDI OCT
 B. ICGA
 C. FA
 D. Wide-field FA
4.  Which of the following diagnoses would you consider most   
 likely when seeing midperipheral retinitis in a patient who is HIV   
 positive?
 A. BSRC
 B. Cytomegalovirus retinitis
 C. Lymphoma
 D. Sarcoidosis
5.  Oral prednisone is initiated to treat a patient with noninfectious   
 posterior uveitis and achieves disease control. Systemic    
 immunosuppression should be considered if: 
 A. The prednisone dose required to maintain chronic suppression   
  exceeds 1 mg/d 
 B. The prednisone dose required to maintain chronic suppression   
  exceeds 5 mg/d
 C. The prednisone dose required to maintain chronic suppression   
  exceeds 10 mg/d
 D. Prednisone cannot be discontinued after 1 month
6.  The VISUAL I and VISUAL II studies investigated adalimumab as 
 a treatment for noninfectious uveitis involving the posterior   
 segment. In both studies, treatment with adalimumab was 
 given as: 
 A. An oral capsule
 B. A subcutaneous injection 
 C. An intravitreal injection
 D. An intravenous infusion
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7.  The anti-inflammatory activity of sirolimus results from:
 A. Binding to lymphocyte function–associated antigen 1 
  expressed on T cells
 B. Inhibition of leukocyte activation and production of    
  proinflammatory cytokines
 C. Integrin receptor inhibition
 D. Interleukin-17 blockade
8.  In an integrated analysis of data from the phase 3 SAKURA   
 studies, statistically significant differences favoring sirolimus   
 440 µg over control treatment, sirolimus 44 μg,  were found for the  
 following end points. 
 A. Vitreous haze score = 0 and vitreous haze score ≤ 0.5
 B. Vitreous haze score = 0 and corticosteroid-tapering success   
  with vitreous haze reduction
 C. Vitreous haze score ≤ 0.5 and corticosteroid-tapering success   
  with vitreous haze reduction
 D. Vitreous haze score ≤ 0.5 and time to treatment failure
9.  A patient with bilateral panuveitis is started on methotrexate 
 10 mg once weekly, with upward titration by 5 mg every 2 weeks   
 to the current dose of 20 mg. At 1 month after starting therapy,   
 there is no improvement in vitreous haze, but VA appears to be   
 stable. An appropriate action would be to:
 A. Switch to cyclophosphamide
 B. Continue the methotrexate at the current dose for an    
  additional 1 to 2 months prior to changing therapy
 C. Start the patient on high-dose corticosteroids
 D. Perform a lumbar puncture to rule out lymphoma
10. A male patient with Behçet disease presents with uveitis   
 involving the posterior segment and is started on high-dose   
 prednisone to control the ocular inflammation. At his 2-week visit,   
 the uveitis appears to be worsening. What is your next step?
 A. Treat with intravenous methylprednisolone and raise the   
  prednisone dose
 B. Inject the dexamethasone implant
 C. Refer the patient to a uveitis specialist
 D. Wait 2 more weeks to see if there is improvement
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below. This ensures that your certificate is filled out correctly and is e-mailed to the proper address. It also enables us to contact you 
about future CME activities. Please print clearly or type. Illegible submissions cannot be processed.
PARTICIPANT INFORMATION (Please Print) ☐ Home  ☐ Office
Last Name ___________________________________________________________ First Name ____________________________________
Specialty ____________________Degree  ☐ MD  ☐ DO  ☐ OD  ☐ PharmD  ☐ RPh  ☐ NP  ☐ RN  ☐ PA ☐ Other
Institution __________________________________________________________________________________________________________
Street Address ______________________________________________________________________________________________________
City _________________________State _________________ ZIP Code ________________Country_______________________________
E-mail ______________________________________________________ Phone______________________Fax_______________________
Please note:  We do not sell or share e-mail addresses. They are used strictly for conducting post-activity follow-up surveys to 
assess the impact of this educational activity on your practice.
Learner Disclosure: To ensure compliance with the US Centers for Medicare and Medicaid Services regarding gifts to physicians, 
New York Eye and Ear Infirmary of Mount Sinai CME requires that you disclose whether or not you have any financial, 
referral, and/or other relationship with our institution. CME certificates cannot be awarded unless you answer this question. 
For additional information, please e-mail NYEE CME at cme-nyee@nyee.edu. Thank you.
☐ Yes  ☐ No    I and/or my family member have a financial relationship with New York Eye and Ear Infirmary of Mount Sinai 
and/or refer Medicare/Medicaid patients to it.
☐ I certify that I have participated in the entire activity and claim 1.5 AMA PRA Category 1 Credits™.
Signature Required ____________________________________________________Date Completed _____________________________
OUTCOMES MEASUREMENT
☐ Yes  ☐ No Did you perceive any commercial bias in any part of this activity? IMPORTANT! If you answered “Yes,” we 
urge you to be specific about where the bias occurred so we can address the perceived bias with the contributor and/or 
in the subject matter in future activities.
____________________________________________________________________________________________________________________
Circle the number that best reflects your opinion on the degree to which the following learning objectives were met:
5 = Strongly Agree  4 = Agree  3 = Neutral  2 = Disagree  1 = Strongly Disagree
Upon completion of this activity, I am better able to:    
• Discuss the use of diagnostic assessments to differentiate between infectious and noninfectious 
 uveitis of the posterior segment
• Assess which patients with noninfectious uveitis of the posterior segment would be referred to 
 a uveitis specialist
• Demonstrate application of evidence-based treatments for a variety of patients with noninfectious 
 uveitis of the posterior segment
• Describe the mechanism of action and clinical trial outcomes for emerging agents in clinical trials 
 for local therapy for noninfectious uveitis of the posterior segment
1.  Please list one or more things, if any, you learned from participating in this educational activity that you did not already know. 
____________________________________________________________________________________________________________________
2.  As a result of the knowledge gained in this educational activity, how likely are you to implement changes in your practice?
 4 = definitely will implement changes  3 = likely will implement changes  2 = likely will not implement any changes 
 1 = definitely will not make any changes                            
Please describe the change(s) you plan to make: _______________________________________________________________________
____________________________________________________________________________________________________________________
3.  Related to what you learned in this activity, what barriers to implementing these changes or achieving better patient outcomes  
 do you face?_____________________________________________________________________________________________________
4.  Number of patients with posterior uveitis I see per week 
 ☐ 0  ☐ 1-5  ☐ 6-10  ☐ 11-25  ☐ More than 25
5.  Please check the Core Competencies (as defined by the Accreditation Council for Graduate Medical Education) that were enhanced  
 for you through participation in this activity. 
 ☐ Patient Care   ☐ Practice-Based Learning and Improvement  ☐ Professionalism
 ☐ Medical Knowledge  ☐ Interpersonal and Communication Skills   ☐ Systems-Based Practice
6. What other topics would you like to see covered in future CME programs? _______________________________________________
ADDITIONAL COMMENTS _____________________________________________________________________________________________
POST TEST ANSWER BOX
ORIGINAL RELEASE: DECEMBER 1, 2017
EXPIRATION: DECEMBER 31, 2018
1 2 3 4 5 6 7 8 9 10
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5       4       3       2       1
5       4       3       2       1
5       4       3       2       1
5       4       3       2       1
5       4       3       2       1
